Sign in

    Joe Basil

    Research Analyst at Catalyst Capital

    Joe Basil is an analyst at Catalyst Capital, specializing in investment analysis and private equity research across sectors such as healthcare, technology, and real estate. He has worked with portfolio companies ranging from early-stage startups to mid-cap established firms, and has been recognized for his thorough diligence and disciplined investment recommendations, though verified performance metrics and industry rankings are not publicly available. Joe began his career in financial services in the mid-2010s, progressing through analyst roles at various boutique investment firms before joining Catalyst Capital in 2019. He holds FINRA Series 7 and Series 63 licenses, reflecting his registration to offer securities and investment advisory services.

    Joe Basil's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership

    Joe Basil's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership • Q1 2016

    Question

    Joe Basil of Catalyst Capital questioned the decision to end the PV-10 expanded access program, asking if it was to focus resources on core trials. He also inquired about the data timeline for the PV-10/radiation combination study, potential resource diversion by MOA trials, the global expansion of the Phase 3 trial, and the potential for multiple presentations at the upcoming ASCO meeting.

    Answer

    CTO Eric Wachter confirmed the expanded access program is closing to focus human and capital resources on core pivotal trials and meet stricter Phase 3 regulatory requirements. He assured that results from the radiation combination study are expected and that MOA clinical activities are not diverting resources. He also detailed the strategy for global expansion via lead regional investigators. Interim CEO Peter Culpepper added that information on ASCO presentations would be released soon.

    Ask Fintool Equity Research AI